Tesamorelin
Stabilized GHRH analog
The only GHRH analog with published trial data specifically targeting visceral adipose tissue reduction.
How it works
Tesamorelin is a stabilized GHRH analog carrying a trans-3-hexenoyl modification that makes it resistant to breakdown by the enzyme DPP-4. This chemical stability allows it to produce a more sustained elevation in growth hormone and downstream IGF-1 levels than unmodified GHRH fragments.
It is the only GHRH analog in this class with dedicated clinical trial data targeting visceral adipose tissue specifically, a fat depot linked to metabolic risk. Researchers propose that sustained GH elevation drives lipolysis preferentially in visceral fat stores.
Because GH signaling is associated with reduced insulin sensitivity at higher levels, tesamorelin trials have consistently monitored glucose markers, and this trade-off is discussed extensively in the published literature alongside its reported benefits in fat reduction.
What research has shown
Clinical trials reported ~15 to 18% reductions in visceral adipose tissue over 26 to 52 weeks, plus reductions in liver fat.
Reported ranges in the literature
Low end
1 mg daily
Optimal
2 mg daily (the trial dose)
High end
2 mg daily; not exceeded in published trials
Frequency reported in the literature: Once daily, typically evening. Note: Glucose markers were monitored in trials due to GH-related insulin resistance.
Frequently asked questions
What is tesamorelin?
Tesamorelin is a stabilized GHRH analog with published clinical trial data specifically examining reductions in visceral adipose tissue.
How does tesamorelin differ from sermorelin?
Tesamorelin includes a chemical modification for DPP-4 resistance and has dedicated trial data on visceral fat, while sermorelin is a shorter, unmodified fragment used more broadly as a GH-axis research tool.
What does the research show?
Clinical trials reported roughly 15 to 18 percent reductions in visceral adipose tissue over 26 to 52 weeks, along with reductions in liver fat.
What monitoring does the literature emphasize?
Glucose markers are consistently tracked in tesamorelin trials due to the known relationship between elevated GH signaling and reduced insulin sensitivity.
How long are research blocks typically?
Published trials generally spanned 26 to 52 weeks to capture meaningful changes in visceral fat volume.
Related compounds
Further reading
Research use only
All content on this page is general reference information for laboratory research contexts. It is not medical advice, is not intended to direct human use, and does not replace guidance from a licensed healthcare professional. Not for human consumption. Must be 18+.